D-Fructose
|
Basic information |
| Metabolite name | D-Fructose |
 | HMDB0000660 |
 |
C02336 |
 |
439709 |
| Synonyms | D-(-)-Fructose; |
| No. of studies | 25 |
|
Basic information |
| Metabolite name | D-Fructose |
| HMDB0000660 |
|
C02336 |
|
439709 |
| Synonyms | D-(-)-Fructose; |
| No. of studies | 25 |
|
Relationship between D-Fructose and depression (count: 25) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M028 | Type2 | placebo group 4-week treatment vs. baseline | Serum | Human | Up |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M042 | Type3 | fluoxetine group vs. control group | Plasma | Rhesus monkey | Down |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Up |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Up |
| Study M480 | Type2 | CGA-treated group vs. sleep deprivation group | Urine | Wistar rat | Down |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Up |
| Study M757 | Type1 | PSD group vs. stroke group | Urine | Human | Up |
| Study M894 | Type1 | electromagnetic field exposure group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M956 | Type2 | CUMS + whey protein-based group vs. CUMS group | Faece | C57BL/6J mouse | Up |